Approaching Shareholders Regarding the Final Deadline of October 6, 2025, for Nominating Lead Plaintiff in the Altimmune Lawsuit - ALT
In a recent development, Altimmune, Inc. is the subject of a class action securities lawsuit following the results of its IMPACT Phase 2b MASH trial. The lawsuit alleges securities fraud and is being led by Levi & Korsinsky, LLP, a renowned firm with extensive expertise in complex securities litigation.
Levi & Korsinsky, LLP boasts a team of over 70 employees and a track record of winning high-stakes cases. The firm has ranked in ISS Securities Class Action Services' Top 50 Report for seven years, securing hundreds of millions of dollars for aggrieved shareholders over the past 20 years.
The lawsuit claims that Altimmune's press release on June 26, 2025, about the IMPACT Phase 2b MASH trial results showed a failure to achieve statistical significance in the fibrosis reduction primary endpoint. This, the lawsuit states, was due to a higher-than-expected placebo response.
Investors in Altimmune who purchased shares between August 10, 2023, and June 25, 2025, may be eligible to participate in the recovery. Participation in the recovery doesn't require serving as a lead plaintiff. The lead plaintiff, who can be identified on October 6, 2025, is not publicly available information.
Investors interested in joining the class action lawsuit have until October 6, 2025, to request appointment as lead plaintiff. Following the news, Altimmune's stock price declined dramatically, from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, a decline of 53.2% in a single day.
Levi & Korsinsky, LLP is the firm representing investors in the Altimmune class action securities lawsuit. Investors can contact Joseph E. Levi at [email protected] or (212) 363-7500 for more information. The contact information for Levi & Korsinsky, LLP is: Joseph E. Levi, Esq., Ed Korsinsky, Esq., 33 Whitehall Street, 17th Floor, New York, NY 10004, [email protected], Tel: (212) 363-7500, Fax: (212) 363-7171, www.zlk.com.
The lawsuit can be found at this link: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form-2?prid=168139&wire=3. It is important to note that there are no out-of-pocket costs or fees for class members entitled to compensation.
This article is intended for informational purposes only and should not be taken as legal advice. For specific questions regarding the Altimmune class action securities lawsuit, investors are encouraged to contact Levi & Korsinsky, LLP directly.
Read also:
- Trade Disputes Escalate: Trump Imposes Tariffs, India Retaliates; threatened boycott ranges from McDonald's, Coca-Cola to iPhones
- Aquatech purchases Koch's Direct Lithium Extraction business, merging Li-ProTM DLE technology into the PEARLTM Technology Platform.
- Nepal's Journey: Evolution from Street Life to Political Power
- Li Auto faces scrutiny after crash test involving i8 model and a truck manufacturer sparks controversy
